Brand-name drug
Simlandi price, strengths & recalls
Brand of adalimumab (generic)
Pharmacies pay $499.25 for 1 kit of Simlandi 100 mg/mL, 0.4 mL auto-injector this week, and from $499.25 to $957.30 across its 2 priced strengths and forms. The generic, adalimumab, costs pharmacies from $490.68. Its official label last changed on July 22, 2026.
Brand- Fair cash price
- $584.64
- Strengths
- 2
- Makers
- 1
- Updated
- Nov 11
Simlandi price by strength
What pharmacies pay for each strength and form this week (Nov 11, 2026), for the usual package. Choose one for its fair price, 52-week chart and makers.
| Strength and form | Per unit | Pharmacies pay |
|---|---|---|
| 100 mg/mL, 0.4 mL auto-injector Brand | $499.25 | $499.25 / 1 kit |
| 100 mg/mL, 0.4 mL prefilled syringe Brand | $478.65 | $957.30 / 2 kits |
Simlandi vs generic adalimumab
There is no generic version of Simlandi on the market yet.
GenericAdalimumab pricesSupply status: shortages & recalls
What people paid for Simlandi
Bought it recently? Share the price, the pharmacy and how you paid - it's the most useful thing the next person can read.
Official label & what changed
These highlights do not include all the information needed to use SIMLANDI safely and effectively. See full prescribing information for SIMLANDI.SIMLANDI® (adalimumab-ryvk) injection, for subcutaneous use Initial U.S. Approval: 2024 SIMLANDI (adalimumab-ryvk) is biosimilarBiosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically meaningful dif
WARNING: SERIOUS INFECTIONS and MALIGNANCY
SERIOUS INFECTIONS
Patients treated with adalimumab products, including SIMLANDI, are at increased risk for developing serious infections that may lead to hospitalization or death
[see Warnings and Precautions (5.1)]. Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids.
Discontinue SIMLANDI if a patient develops a serious infection or sepsis.
Reported infections include:
Active tuberculosis (TB), including reactivation of latent TB. Patients with TB have frequently presented with disseminated or extrapulmonary disease. Test patients for latent TB before SIMLANDI use and during therapy. Initiate treatment for latent TB prior to SIMLANDI use.
Invasive fungal infections, including histoplasmosis, coccidioidomycosis, candidiasis, aspergillosis, blastomycosis, and pneumocystosis. Patients with histoplasmosis or other invasive fungal infections may present with disseminated, rather than localized, disease. Antigen and antibody testing for histoplasmosis may be negative in some patients with active infection. Consider empiric anti-fungal therapy in patients at risk for invasive fungal infections who develop severe systemic illness.
Bacterial, viral and other infections due to opportunistic pathogens, including Legionella and Listeria.
Carefully consider the risks and benefits of treatment with SIMLANDI prior to initiating therapy in patients with chronic or recurrent infection.
Monitor patients closely for the development of signs and symptoms of infection during and after treatment with SIMLANDI, including the possible development of TB in patients who tested negative for latent TB infection prior to initiating therapy
[see Warnings and Precautions (5.1) and Adverse Reactions (6.1)].
MALIGNANCY
Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with TNF blockers including adalimumab products
[see Warnings and Precautions (5.2)]. Post-marketing cases of hepatosplenic T-cell lymphoma (HSTCL), a rare type of T-cell lymphoma, have been reported in patients treated with TNF blockers including adalimumab products. These cases have had a very aggressive disease course and have been fatal. The majority of reported TNF blocker cases have occurred in patients with Crohn's disease or ulcerative colitis and the majority were in adolescent and young adult males. Almost all these patients had received treatment with azathioprine or 6-mercaptopurine (6-MP) concomitantly with a TNF blocker at or prior to diagnosis. It is uncertain whether the occurrence of HSTCL is related to use of a TNF blocker or a TNF blocker in combination with these other immunosuppressants
[see Warnings and Precautions (5.2)].
WARNING: SERIOUS INFECTIONS and MALIGNANCY
See full prescribing information for complete boxed warning.
SERIOUS INFECTIONS (5.1,
6.1):
Increased risk of serious infections leading to hospitalization or death, including tuberculosis (TB), bacterial sepsis, invasive fungal infections (such as histoplasmosis), and infections due to other opportunistic pathogens.
Discontinue SIMLANDI if a patient develops a serious infection or sepsis during treatment.
Perform test for latent TB; if positive, start treatment for TB prior to starting SIMLANDI.
Monitor all patients for active TB during treatment, even if initial latent TB test is negative.
MALIGNANCY (5.2):
Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with TNF blockers including adalimumab products.
Post-marketing cases of hepatosplenic T-cell lymphoma (HSTCL), a rare type of T-cell lymphoma, have occurred in adolescent and young adults with inflammatory bowel disease treated with TNF blockers including adalimumab products.
Recent major changes (as listed on the label)
Indications and Usage, Hidradenitis Suppurativa (1.8) 10/2025
Indications and Usage, Uveitis (1.9) 10/2025
Dosage and Administration, Recommended Dosage in Juvenile Idiopathic Arthritis or Pediatric Uveitis (2.3) 10/2025
Dosage and Administration, Recommended Dosage in Hidradenitis Suppurativa (2.6) 10/2025
Warnings and Precautions, Autoimmunity (5.9) 10/2025
Indications and Usage, Hidradenitis Suppurativa (1.8) 10/2025
Indications and Usage, Uveitis (1.9) 10/2025
Dosage and Administration, Recommended Dosage in Juvenile Idiopathic Arthritis or Pediatric Uveitis (2.3) 10/2025
Dosage and Administration, Recommended Dosage in Hidradenitis Suppurativa (2.7) 10/2025
Warnings and Precautions, Autoimmunity (5.9) 10/2025
We check this label every day. When it changes, the sections that changed appear here, old text beside new.
We show the official text and what changed; we don't interpret it. Ask your pharmacist or prescriber what a change means for you.
Approval, patents & generics
- Application
- BLA761299 · Alvotech USA Inc
- First approved
- February 23, 2024 (2 years ago)
- Latest approved change
- November 6, 2025
- Approved label
- PDF, Nov 7, 2025
- Generic makers
- None on the market
Simlandi questions
How much does simlandi cost without insurance?
Pharmacies pay about $499.25 for 1 kit of simlandi 100 mg/mL, 0.4 mL auto-injector ($499.25 per unit). A fair cash price - that cost plus a 15% margin and a typical dispensing fee - is about $584.64. If you're quoted much more, check your quote and ask for the pharmacy's cash price.
Is there a generic for Simlandi?
Yes: adalimumab. Pharmacies pay from $490.68 for it. Compare adalimumab prices.
Is simlandi in shortage?
No shortage is reported for simlandi right now. We check the national shortage list every day.
Has simlandi been recalled?
No recalls are on record for simlandi.
When did the simlandi label last change?
The official label was last updated on July 22, 2026 (version 26). See what changed.
Talk about simlandi
No comments yet. Questions, tips, what worked for you - start the conversation.